Allscripts: Veradigm Strength to Offset Declining Core Revenue in 2022

Equity Analyst

Dylan Finley

Allscripts is a provider of healthcare IT services, with a wide portfolio of software targeting the operational and financial management needs of hospitals and physician offices. The company’s core offering is its suite of electronic health record (EHR) solutions--the electronic record of a patient’s medical history. In the acute hospital space, Allscripts’ market share significantly lags competitors Epic and Cerner, which combined represent a majority of the market. Allscripts’ relative strength in the more fragmented physician office EHR market has been subject to erosion in recent years, due to the trend of practice acquisition by integrated delivery networks (i.e. hospital systems). The EHR market is highly mature, and the technology is ubiquitous across medical care settings--early movers like Epic and Cerner have been the primary beneficiaries of the industry boon following the introduction of federal subsidies (Hitech Act of 2009) and overall trends toward digitization over the past decade and a half. The hospital EHR replacement market has largely favored Epic over the past few years, and Allscripts has largely been focused on the smaller community hospital setting. 

The company’s future growth opportunity lies the monetization of its data through standalone data offerings (tailored to payers and life sciences companies) and add-on tools to the EHR suite enhancing physician workflows and patient outcomes. This strategy is hardly differentiated from competitors--Cerner has invested in similar strategic growth areas over the past few years (population health management and data-as-a-service offerings). Allscripts surprised the market in October 2020 with its $1.3 billion sale of its care coordination software, CarePort. The transaction valued CarePort at 13 times annual revenue, significantly higher than the market valuation of the standalone company.

Business Strategy & Outlook

Allscripts’ comparatively weak positioning and unfavorable outlook in the electronic health record (EHR) software market are the primary determinants of our no-moat assessment. While multiyear contracts and the traditionally high switching costs associated with replacing an EHR vendor partially insulate the company from client erosion, Allscripts has a significantly smaller market share and weaker competitive positioning in the stickier and more lucrative hospital EHR market, compared with rivals Epic and Cerner. In these settings, the direct cost and expense of switching to a competing solution is very high both in terms of costs (roughly $25,000 to $75,000 per physician to implement) and in terms of operational disruption within the hospital. Furthermore, the hospital EHR market is fully mature with over 96% of non-federal acute care hospitals possessing an HHS certified EHR (per HealthIT.gov). The remaining opportunity--the replacement market--has largely skipped over Allscripts, with privately held Epic’s best-of-breed EHR platform dominating the market for larger hospitals and health networks, and Cerner having won a $16 billion contract to upgrade federal (Dept. of Veteran Affairs) hospitals through 2028. Additionally, while the Allscripts’ Veradigm business segment--a catchall for its data offerings--has exhibited stronger growth and relatively higher margins, we fail to see any meaningful differentiation over Epic and Cerner’s own nascent data offerings. 

Sunrise, Allscripts’s flagship hospital EHR, is a comprehensive platform that combines the core functionality of the EHR (patient details, medical history, labs, treatments, etc.) with operational and revenue cycle solutions (payment management and collection). Allscripts’ focus on the physician market during the rapid period of hospital EHR technology adoption in the early 2010s left the company with a comparatively small share of the market (midsingle digits). The rate of adoption occurred rapidly in part due to substantial government subsidies (2009 Hitech Act’s meaningful use incentive), pushing forward demand and trends toward digitalization and giving a substantial benefit to companies with an early mover advantage (i.e. Epic and Cerner). EHR software is particularly sticky, not only due to the high cost of system implementation but due to the operational disruption resulting from switching vendors. Beyond the loss in productivity associated with new system training and data transfer, the risks extend to patient lives’ themselves, so hospital administrations are highly risk-averse when making major operational changes to their EHR technology. 

While there is virtually no remaining greenspace in the industry, the replacement market has favored Epic’s best-in-class EHR offerings, particularly in the large hospital network setting. As a result, Allscripts’ has shifted its focus to retaining its current client base and looks to expand its offerings primarily in rural areas and in the community hospital setting. These hospitals typically have fewer resources, making a system like Epic less attractive. Allscripts’ primary competitor in this market is Cerner--which also places an emphasis on the community hospital setting. 

Allscripts’ positioning in the ambulatory EHR market for physician offices has weakened in recent years. Compared with the hospital market, the number of vendors and degree of market fragmentation are much higher. Despite Allscripts’ early efforts in the space, according to a 2018 analysis conducted by KPMG, Allscripts only trails Epic in market share and holds around 9% of the physician office market. Limited transparency and disclosure by Allscripts in the segment make it difficult to ascertain more recent trends; however, given the lack of innovation or product differentiation, it is unlikely any changes in the market have played out favorably for Allscripts. Additionally, based on user reviews aggregated by Capterra, a software guide and review site for businesses, Allscripts’ Professional EHR garners reviews at the low end compared with other top vendors (3.4 out of 5 as of January 2022). Epic’s ambulatory EHR proves to be the leader in the space by user satisfaction (4.3 out of 5), with other large competing vendors falling in between (eClinicalWorks, NextGen Healthcare, athenaOne, Cerner PowerChart). 

Allscripts’ growth and profitability are highly dependent on the performance of the company’s Veradigm segment--which includes health information data and analytics. The company touts Veradigm as having the largest de-identified ambulatory patient records available, which the company is able to monetize by selling to payers and PBMs, or by selling to life sciences companies as real-world data, used in conjunction with clinical trials in the drug development process. The largest shortcoming with Allscripts’ data offerings is its lack of substantial market share in the acute hospital EHR market, putting it at a disadvantage versus the wealth of data available to Epic and Cerner. These areas are of focus to Epic and Cerner as well, and we find it unlikely that Allscripts will be able to leverage its data more effectively than its better equipped peers.

None

Economic Moat

Allscripts Healthcare Solutions

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (Nasdaq: MDRX) announced today that, on September 20, 2023 and as anticipated in its September 18 release, it received a notice from Nasdaq indicating that the Company's shares would be delisted due to noncompliance with Nasdaq Listing Rule 5250(c)(1), because the Company did not file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Form 10-Q”.

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Veradigm Inc. is a small-cap firm in the healthcare industry and its stock is trading near its 52-week low. The company was birthed out of Allscripts Healthcare Solutions, and the new entity provides data and analytics tools to healthcare providers. Veradigm's financial reports have been delayed, and it is likely to receive a delisting notice from NASDAQ.

Veradigm: Some Promise Combined With Uncertainty

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (Nasdaq: MDRX) announced today that the work effort to conclude on its previously disclosed accounting and internal control errors has taken longer than previously expected, and more time is needed to complete its audit procedures. As such, today the Company will not be filing its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), or its Quarterly Reports on Forms 10-Q for the quarters ended March 31, 2023, and June 30, 202.

Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023

NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ: MDRX) concerning possible violations of federal securities laws.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Veradigm Inc.

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Form 10-Q”) and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Q2 For.

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

NEW YORK , Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Veradigm Inc. ("Veradigm") (NASDAQ: MDRX) violated federal securities laws. CURRENT INVESTIGATION DETAILS:Veradigm announced on February 28, 2023 that they had discovered internal control failures related to revenue recognition over the previous six quarters, resulting in misstated reported revenues during that time.

MDRX NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Veradigm Inc.

NEW YORK , July 31, 2023 /PRNewswire/ -- Attention Veradigm Inc. ("Veradigm") (NASDAQ: MDRX) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Veradigm and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: Veradigm announced on February 28, 2023 that they had discovered internal control failures related to revenue recognition over the previous six quarters, resulting in misstated reported revenues during that time.

MDRX ALERT: The Law Offices of Vincent Wong Investigate Veradigm Inc. for Potential Violations of Securities Laws

NEW YORK , July 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Veradigm Inc. (NASDAQ: MDRX) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/veradigm-class-action-loss-submission-form/?id=42678&from=4 Further details on the investigation: Veradigm announced on February 28, 2023 that they had discovered internal control failures related to revenue recognition over the previous six quarters, resulting in misstated reported revenues during that time. This has led to an expected reduction in revenue of approximately $20 million dollars from what was reported in the third quarter of 2021 and what was expected to be reported in the fourth quarter of 2022.

MDRX FRAUD ALERT: Jakubowitz Law is Investigating Veradigm Inc. in Connection with Potential Violations of Federal Securities Laws

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (NASDAQ: MDRX) announced today the signing of two multi-year healthcare provider agreements during the second quarter. One of Veradigm's largest Veradigm EHR clients, State of Franklin Healthcare Associates (SOFHA), a physician-owned and led primary care and multi-specialty healthcare system in upper East Tennessee and Southwest Virginia, expanded its agreement with Veradigm to include Veradigm Revenue Cycle Services. “SOFHA is comprised of over 250+ prov.

Veradigm Announces New and Expanded Provider Partnerships

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (NASDAQ: MDRX) reports today strong growth for the preceding six months in its payer segment including: 296 Veradigm Payerpath agreements 6 net-new regional payer, national payer, and aggregator clients signed 16 incremental health plan agreements signed with existing clients, including the new Comprehensive Submissions which increased Veradigm's footprint in the Medicaid market Signed the first two Veradigm Payer Insight contracts, breaking ground in the.

Veradigm Increasing Presence in Payer Market

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (Nasdaq: MDRX) announced today that Nasdaq has accepted the Company's plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and granted the Company an exception until September 18, 2023 to file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) and Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Form 10-Q”). The Company received notice from Nasdaq on March 20, 2023, that it was not in com.

Veradigm Inc. Receives Approval from Nasdaq of Plan to Regain Listing Compliance

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced that Black Book, a healthcare-centric market research and public opinion research and consulting company, has honored Veradigm Payerpath with the highest ranking in its End-to-End RCM Software Technology, Physician Practices & Ambulatory Facilities/Groups category for 2023. Black Book conducted polls and surveys with healthcare executives and front-line users about t.

Veradigm Payerpath™ Rated #1 End-to-End Revenue Cycle Management (RCM) Software

Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

NEW YORK , March 30, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Veradigm Inc. (NASDAQ: MDRX) resulting from allegations that Veradigm may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Veradigm securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Veradigm Inc. Investors to Inquire About Class Action Investigation - MDRX

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.

Veradigm Network Solution Practice Fusion EHR Receives Top Ranking

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm Inc. (NASDAQ: MDRX), announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the Company filed with the SEC a Form 12b-25, extending the due date of its annual report on Form 10-K by 15 days, to allow for completion of those procedures.

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results

NEW YORK , March 20, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Veradigm Inc. (NASDAQ: MDRX) resulting from allegations that Veradigm may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Veradigm securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RANKED AND LEADING FIRM, Encourages Veradigm Inc. Investors to Inquire About Class Action Investigation - MDRX

CHICAGO--(BUSINESS WIRE)-- #healthIT--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.

Veradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ Research

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Veradigm Inc. ('Veradigm" or the "Company") (NASDAQ: MDRX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veradigm Inc. - MDRX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Veradigm Inc. (NASDAQ: MDRX) resulting from allegations that Veradigm may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Veradigm securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Veradigm Inc. Investors to Inquire About Class Action Investigation – MDRX

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Veradigm Inc. (“Veradigm” or the “Company”) (NASDAQ: MDRX) on behalf of Veradigm stockholders. Our investigation concerns whether Veradigm has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action.

VERADIGM ALERT: Bragar Eagel & Squire, P.C. is Investigating Veradigm Inc. on Behalf of Veradigm Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Veradigm Inc. ("Veradigm" or "the Company") (NASDAQ: MDRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Veradigm Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $MDRX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Veradigm Inc. (“Veradigm” or the “Company”) (NASDAQ: MDRX). Investors who purchased Veradigm securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mdrx. The investigation concerns whether Veradigm has violated federal securities laws.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Veradigm Inc. (MDRX) Investigation

LOS ANGELES , March 2, 2023 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its an investigation on behalf of Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ: MDRX) investors concerning the Company's possible violations of the federal securities laws.   If you suffered a loss on your Veradigm investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Veradigm-Inc/.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Veradigm Inc. (MDRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $MDRX #MDRX--The Schall Law Firm Announces it is Investigating Claims Against Veradigm Inc.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Veradigm Inc. and Encourages Investors with Losses to Contact the Firm

News for Allscripts Healthcare Solutions Stock (MDRX)